drugset / Trial / NCT03962296

A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®

NCT03962296

Phase 4 Completed 153 enrolled Hanyang University Hanlim Pharm. Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a multicentre, randomised, double-blind controlled study that compared the efficacy and safety of V. vinifera extract, calcium dobesilate (CD), and placebo in subjects with DME. Patients made 6 clinic visits, namely the screening visit; baseline visit (T0); and follow-up visits at 3 (T3), 6 (T6), 9 (T9), and 12 (T12) months.

Timeline

Start
2012-11-21
Primary completion
2015-01-26
Completion
2015-01-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium Dobesilate Unknown 250 mg Oral
Subject Vitis vinifera extract Unknown 50 mg Oral

Indications